Background Despite increased attention paid to assessment and management, pain
continues to be a prevalent and undertreated symptom in patients with cancer. Intrathecal …

Objectives Cancer pain is common and difficult to treat, as conservative medical
management fails in approximately 20% of patients for reasons such as intolerable side …

Objectives Intrathecal drug delivery systems (IDDS) and spinal cord stimulation (SCS) have
been proposed and assessed for the management of cancer pain; however, such treatments …

Intrathecal drug delivery is an effective pain management option for patients with chronic
and cancer pain. The delivery of drugs into the intrathecal space provides superior …

Background Cancer pain prevalence remains high with more than 60% of patients with
advanced cancer experiencing cancer-related pain. The undertreatment of pain due to …

Background: Chronic persistent pain as a result of terminal illness, either as a consequence
of the disease or the necessary treatment, is common in patients with cancer. For these …

Background Intrathecal drug delivery (IDD) system with implantable pumps has been used
to treat cancer‐related pain as well as noncancer‐related chronic pain. Opioids, including …

Objective Intrathecal (IT) drug delivery has shown its efficiency in treating refractory cancer
pain, but switching opioids from the systemic to the intrathecal route is a challenging phase …

BACKGROUND: The safety and efficacy of intrathecal drug delivery systems (IDDSs) for the
treatment of cancer-related pain have been demonstrated in randomized controlled clinical …

Objectives Pain is common in cancer, affecting more than 70% of patients with advanced
disease. Intrathecal drug delivery systems (IDDS) are a well-established treatment for …